Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Duloxetine + warfarin is a combination of two pharmaceutical drugs. Duloxetine is a serotonin-norepinephrine reuptake inhibitor (SNRI) antidepressant, primarily inhibiting the reuptake of serotonin and norepinephrine, thereby increasing their availability in the synaptic cleft and improving mood and pain symptoms. Warfarin is a vitamin K antagonist anticoagulant that inhibits vitamin K-dependent synthesis of biologically active forms of clotting factors II, VII, IX, and X, reducing blood coagulation and risk of thrombosis. The combination is not marketed as a fixed-dose product, but these drugs are sometimes co-prescribed, for example, in patients requiring anticoagulation (e.g., for atrial fibrillation or venous thromboembolism) who also have depression or neuropathic pain. Coadministration can increase bleeding risk, likely due to duloxetine’s impairment of platelet function as well as pharmacodynamic interactions, but pharmacokinetic interaction is minimal. Careful monitoring of bleeding and INR is recommended during concomitant administration[1][2][4][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on duloxetine + warfarin.